Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 3418.

https://doi.org/10.1182/blood-2025-3418

Published: 2025

Journal Articles

Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial

Zhifeng Li, Hua Wang, Zhijuan Lin, Li Yu, Shaojie Wu, Na Qin, Jie Zha, Long Liu, Manman Deng, Bing Xu

Blood (2025) 146 (Supplement 1): 3580.

https://doi.org/10.1182/blood-2025-3580

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 3896.

https://doi.org/10.1182/blood-2025-3896

Published: 2025

Journal Articles

Adoptive T-cell therapy targeting a novel non-canonical neoantigen derived from a translated AML1-ETO lncrna shows clinical activity in a first-in-human trial for t(8;21) AML

Weijie Liao, Jianglong Xia, Ruocong Zhao, Chenguang Wang, Li Yu, Lixin Wang

Blood (2025) 146 (Supplement 1): 6949.

https://doi.org/10.1182/blood-2025-6949

Published: 2025

Journal Articles

Plasma proteomic profiles predict future non-Hodgkin lymphoma in healthy adults

Qing Luo, Yi Luo, Li Yu

Blood (2025) 146 (Supplement 1): 5334.

https://doi.org/10.1182/blood-2025-5334

Published: 2025

Journal Articles

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Blood (2025) 146 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2025-1957

Published: 2025

Journal Articles

Updated clinical outcomes of a Phase I/II trial of bispecific CD19/CD20-targeted CAR-T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Chuling Fang, Lixin Wang, Yuanyuan Zheng, Weiqiang Zhao, Yuanyuan Xu, Wenfa Huang, Li Yu

Blood (2025) 146 (Supplement 1): 1946.

https://doi.org/10.1182/blood-2025-1946

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2025-1001

Published: 2025

Journal Articles

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Blood (2025) 146 (9): 1065–1077.

https://doi.org/10.1182/blood.2025028357

Published: 2025

Includes: Supplemental data

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Journal Articles

Predictive Value and Modeling of Peripheral Blood Lymphocyte Subsets for the Treatment of Diffuse Large B-Cell Lymphoma

Wang Ya, Li Yu, Yi Luo

Blood (2024) 144 (Supplement 1): 6270.

https://doi.org/10.1182/blood-2024-202308

Published: 2024

Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood (2024) 144 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2024-194572

Published: 2024

Journal Articles

Molecular Mechanism of c-Myc Nuclear Output Mediated By m5C Binding Protein Alyref in c-Myc+ DLBCL

Lili Zhou, Yi Luo, Li Yu

Blood (2024) 144 (Supplement 1): 5755.

https://doi.org/10.1182/blood-2024-206558

Published: 2024

Journal Articles

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Blood (2024) 144 (Supplement 1): 211.

https://doi.org/10.1182/blood-2024-194384

Published: 2024

Journal Articles

Latest Update Results of Cmoep Regimen in Treatment-Naive Patients with Peripheral T-Cell Lymphoma

Jingwei Yu, Xiuhua Sun, Guangxun Gao, Li Yu, Jiesong Wang, Lihua Qiu, Zhengzi Qian, Wei Li, Huilai Zhang

Blood (2024) 144 (Supplement 1): 6403.

https://doi.org/10.1182/blood-2024-204337

Published: 2024

Journal Articles

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Jie Jin, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen, Qingqing Cai

Blood (2024) 144 (Supplement 1): 6368.

https://doi.org/10.1182/blood-2024-211891

Published: 2024

Journal Articles

The Role of Artificial Intelligence in Differential Diagnosis and Prognostic Significance of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Zizhu Tian, Yue Sheng, Fangjian Han, Li Yu, Zeyu Deng, Yi Jiang, Hongling Peng

Blood (2024) 144 (Supplement 1): 6326.

https://doi.org/10.1182/blood-2024-201479

Published: 2024

Journal Articles

Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Yuankai Shi, Jianliang Yang, Yongping Song, Keshu Zhou, Zhiming Li, Mingzhi Zhang, Hongmei Jing, Zhen Wang, Li Yu, Wei Meng, Qiying Lu, Wenzhi Tian

Blood (2024) 144 (Supplement 1): 1632.

https://doi.org/10.1182/blood-2024-200499

Published: 2024

Journal Articles

The Molecular Mechanism of CD36 in Regulating Cholesterol Metabolism Reprogramming to Drive the Pathogenesis of Diffuse Large B-Cell Lymphoma Cells

Wei Cheng, Lili Zhou, Qingqing Luo, Yi Luo, Li Yu

Blood (2024) 144 (Supplement 1): 5769.

https://doi.org/10.1182/blood-2024-206523

Published: 2024

Journal Articles

Identifying the Key Genes of Epstein Barr Virus Regulated Tumour Immune Microenvironment of Diffuse Large B Cell Lymphoma

Qingqing Luo, Li Yu, Yi Luo

Blood (2024) 144 (Supplement 1): 5766.

https://doi.org/10.1182/blood-2024-203021

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Adoptive T-cell therapy targeting a novel non-canonical neoantigen derived from a translated AML1-ETO lncrna shows clinical activity in a first-in-human trial for t(8;21) AML

Plasma proteomic profiles predict future non-Hodgkin lymphoma in healthy adults

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Updated clinical outcomes of a Phase I/II trial of bispecific CD19/CD20-targeted CAR-T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Predictive Value and Modeling of Peripheral Blood Lymphocyte Subsets for the Treatment of Diffuse Large B-Cell Lymphoma

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Molecular Mechanism of c-Myc Nuclear Output Mediated By m5C Binding Protein Alyref in c-Myc+ DLBCL

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Latest Update Results of Cmoep Regimen in Treatment-Naive Patients with Peripheral T-Cell Lymphoma

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

The Role of Artificial Intelligence in Differential Diagnosis and Prognostic Significance of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

The Molecular Mechanism of CD36 in Regulating Cholesterol Metabolism Reprogramming to Drive the Pathogenesis of Diffuse Large B-Cell Lymphoma Cells

Identifying the Key Genes of Epstein Barr Virus Regulated Tumour Immune Microenvironment of Diffuse Large B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only